{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:45:50Z","timestamp":1792014350695,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.vaccine.2007.03.028","type":"journal-article","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T07:10:16Z","timestamp":1175584216000},"page":"4437-4446","source":"Crossref","is-referenced-by-count":58,"title":["A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination"],"prefix":"10.1016","volume":"25","author":[{"given":"Juliana","family":"Cassataro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina A.","family":"Pasquevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia M.","family":"Estein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Laplagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Velikovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"de la Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo H.","family":"Giambartolomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando A.","family":"Goldbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2007.03.028_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CMR.16.1.65-78.2003","article-title":"Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans","volume":"16","author":"Ko","year":"2003","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.028_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/clinids\/21.2.283","article-title":"An overview of human brucellosis","volume":"21","author":"Young","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2007.03.028_bib3","series-title":"Brucella ovis. In Animal brucellosis","first-page":"352","author":"Blasco","year":"1990"},{"issue":"3","key":"10.1016\/j.vaccine.2007.03.028_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0749-0720(15)30840-9","article-title":"Epididymitis in rams and lambs","volume":"6","author":"Bulgin","year":"1990","journal-title":"Vet Clin North Am Food Anim Pract"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.028_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0034-5288(18)30992-5","article-title":"Comparison of subcutaneous and conjunctival routes of Rev 1 vaccination for the prophylaxis of Brucella ovis infection in rams","volume":"48","author":"Marin","year":"1990","journal-title":"Res Vet Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.028_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1051\/vetres:2003037","article-title":"Rough vaccines in animal brucellosis: structural and genetic basis and present status","volume":"35","author":"Moriyon","year":"2004","journal-title":"Vet Res"},{"issue":"8874","key":"10.1016\/j.vaccine.2007.03.028_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0140-6736(93)91571-3","article-title":"Brucella melitensis Rev-1 vaccine as a cause of human brucellosis","volume":"342","author":"Blasco","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.028_bib8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/IAI.62.2.632-638.1994","article-title":"Protective immunity to Brucella ovis in BALB\/c mice following recovery from primary infection or immunization with subcellular vaccines","volume":"62","author":"Jimenez de Bagues","year":"1994","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2007.03.028_bib9","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1128\/IAI.71.10.5750-5755.2003","article-title":"Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used","volume":"71","author":"Velikovsky","year":"2003","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2007.03.028_bib10","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1074\/jbc.M312035200","article-title":"High order quaternary arrangement confers increased structural stability to Brucella sp. lumazine synthase","volume":"279","author":"Zylberman","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.vaccine.2007.03.028_bib11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1128\/IAI.70.5.2507-2511.2002","article-title":"A DNA vaccine encoding lumazine synthase from Brucella abortus induces protective immunity in BALB\/c mice","volume":"70","author":"Velikovsky","year":"2002","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2007.03.028_bib12","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.176.4.2366","article-title":"A polymeric bacterial protein activates dendritic cells via TLR4","volume":"176","author":"Berguer","year":"2006","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2007.03.028_bib13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.micinf.2005.12.006","article-title":"Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity","volume":"8","author":"Rosas","year":"2006","journal-title":"Microbes Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2007.03.028_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/prot.20248","article-title":"Engineering of a polymeric bacterial protein as a scaffold for the multiple display of peptides","volume":"57","author":"Laplagne","year":"2004","journal-title":"Proteins"},{"issue":"3","key":"10.1016\/j.vaccine.2007.03.028_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1099\/00222615-34-3-175","article-title":"Protection conferred on mice by monoclonal antibodies directed against outer-membrane-protein antigens of Brucella","volume":"34","author":"Cloeckaert","year":"1991","journal-title":"J Med Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.028_bib16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1099\/00222615-37-2-100","article-title":"Protection conferred on mice by combinations of monoclonal antibodies directed against outer-membrane proteins or smooth lipopolysaccharide of Brucella","volume":"37","author":"Jacques","year":"1992","journal-title":"J Med Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2007.03.028_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1286-4579(00)00317-8","article-title":"Identification of protective outer membrane antigens of Brucella ovis by passive immunization of mice with monoclonal antibodies","volume":"2","author":"Bowden","year":"2000","journal-title":"Microbes Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2007.03.028_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1099\/00222615-43-5-344","article-title":"Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis","volume":"43","author":"Bowden","year":"1995","journal-title":"J Med Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2007.03.028_bib19","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1128\/IAI.64.9.3744-3751.1996","article-title":"Cloning, nucleotide sequence, and expression of the Brucella melitensis omp31 gene coding for an immunogenic major outer membrane protein","volume":"64","author":"Vizcaino","year":"1996","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2007.03.028_bib20","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1128\/IAI.69.11.7020-7028.2001","article-title":"Minor nucleotide substitutions in the omp31 gene of Brucella ovis result in antigenic differences in the major outer membrane protein that it encodes compared to those of the other Brucella species","volume":"69","author":"Vizcaino","year":"2001","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2007.03.028_bib21","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1128\/IAI.73.12.8079-8088.2005","article-title":"Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+T helper 1 response that protects against Brucella melitensis infection","volume":"73","author":"Cassataro","year":"2005","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.028_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1286-4579(02)00075-8","article-title":"The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB\/c mice","volume":"5","author":"Estein","year":"2003","journal-title":"Microbes Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2007.03.028_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0264-410X(98)00205-9","article-title":"Immunogenicity of recombinant Escherichia coli expressing the omp31 gene of Brucella melitensis in BALB\/c mice","volume":"17","author":"Guilloteau","year":"1999","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2007.03.028_bib24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1099\/00222615-48-9-833","article-title":"The 18-kDa cytoplasmic protein of Brucella species \u2013 an antigen useful for diagnosis \u2013 is a lumazine synthase","volume":"48","author":"Goldbaum","year":"1999","journal-title":"J Med Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.028_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CDLI.11.1.111-114.2004","article-title":"Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae","volume":"11","author":"Cassataro","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2007.03.028_bib26","series-title":"Brucella melitensis","first-page":"215","article-title":"Rev.1 and H38 Brucella melitensis vaccines","author":"Alton","year":"1985"},{"issue":"10","key":"10.1016\/j.vaccine.2007.03.028_bib27","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/IAI.73.10.6537-6546.2005","article-title":"A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response","volume":"73","author":"Cassataro","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2007.03.028_bib28","unstructured":"FAO-WHO."},{"issue":"10","key":"10.1016\/j.vaccine.2007.03.028_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0264-410X(96)00018-7","article-title":"Immunization of mice with recombinant L7\/L12 ribosomal protein confers protection against Brucella abortus infection","volume":"14","author":"Oliveira","year":"1996","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2007.03.028_bib30","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0264-410X(94)90035-3","article-title":"Modulation of immune responses in Balb\/c mice vaccinated with Brucella abortus Cu\u2013Zn superoxide dismutase synthetic peptide vaccine","volume":"12","author":"Tabatabai","year":"1994","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.028_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1099\/0022-1317-49-2-165","article-title":"Identification and partial characterisation of a new protective antigen of Brucella abortus","volume":"49","author":"Cespedes","year":"2000","journal-title":"J Med Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2007.03.028_bib32","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1128\/IAI.69.8.4816-4822.2001","article-title":"Protection of BALB\/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant","volume":"69","author":"Al-Mariri","year":"2001","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2007.03.028_bib33","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1128\/IAI.73.11.7297-7303.2005","article-title":"Selection of protective epitopes for Brucella melitensis by DNA vaccination","volume":"73","author":"Yang","year":"2005","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2007.03.028_bib34","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1128\/IAI.74.5.2734-2741.2006","article-title":"Protective immunity elicited by a divalent DNA vaccine encoding both the L7\/L12 and Omp16 genes of Brucella abortus in BALB\/c mice","volume":"74","author":"Luo","year":"2006","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.028_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0161-5890(96)00096-X","article-title":"Immunons revisited: binding of multivalent antigens to B cells","volume":"34","author":"Sulzer","year":"1997","journal-title":"Mol Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2007.03.028_bib36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/jmbi.2000.3640","article-title":"Divergence in macromolecular assembly: X-ray crystallographic structure analysis of lumazine synthase from Brucella abortus","volume":"297","author":"Braden","year":"2000","journal-title":"J Mol Biol"},{"issue":"11","key":"10.1016\/j.vaccine.2007.03.028_bib37","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.4049\/jimmunol.169.11.6120","article-title":"Determinants of autoantibody induction by conjugated papillomavirus virus-like particles","volume":"169","author":"Chackerian","year":"2002","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2007.03.028_bib38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0167-5699(96)10066-9","article-title":"The influence of virus structure on antibody responses and virus serotype formation","volume":"17","author":"Bachmann","year":"1996","journal-title":"Immunol Today"},{"issue":"6","key":"10.1016\/j.vaccine.2007.03.028_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0161-5890(01)00077-3","article-title":"Native-like, long synthetic peptides as components of sub-unit vaccines: practical and theoretical considerations for their use in humans","volume":"38","author":"Demotz","year":"2001","journal-title":"Mol Immunol"},{"issue":"21\u201322","key":"10.1016\/j.vaccine.2007.03.028_bib40","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.vaccine.2004.01.001","article-title":"Development and evaluation as vaccines in mice of Brucella melitensisRev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis","volume":"22","author":"Cloeckaert","year":"2004","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07003350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07003350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T02:27:26Z","timestamp":1587436046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07003350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":40,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0264410X07003350"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.03.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}